Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The FLAGSHIP Study: A 12-week Phase II Study to Evaluate the Efficacy and Safety of AQX-1125 Following Exacerbations in Patients With Chronic Obstructive Pulmonary Disease (COPD) by Targeting the SHIP1 Pathway

NCT01954628 is registered in ClinicalTrials.gov with Aquinox Pharmaceuticals (Canada) Inc. as lead sponsor.

NCT NCT01954628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01954628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The FLAGSHIP Study: A 12-week Phase II Study to Evaluate the Efficacy and Safety of AQX-1125 Following Exacerbations in Patients With Chronic Obstructive Pulmonary Disease (COPD) by Targeting the SHIP1 Pathway
Lead sponsor
Aquinox Pharmaceuticals (Canada) Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2013
Completion date
December 31, 2015
Enrollment
400 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

copd